CO6260140A2 - Nuevos moduladores del receptor de progesterona - Google Patents
Nuevos moduladores del receptor de progesteronaInfo
- Publication number
- CO6260140A2 CO6260140A2 CO09122568A CO09122568A CO6260140A2 CO 6260140 A2 CO6260140 A2 CO 6260140A2 CO 09122568 A CO09122568 A CO 09122568A CO 09122568 A CO09122568 A CO 09122568A CO 6260140 A2 CO6260140 A2 CO 6260140A2
- Authority
- CO
- Colombia
- Prior art keywords
- dibenzo
- pyrido
- group
- compound according
- thiazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Abstract
La presente invención proporciona nuevos moduladores del receptor de progesterona que son dibenzo[b,f]pirido[1,2-d]oxazepina-2-aminas o dibenzo[b,f]pirido[1,2-d]tiazepina-2-aminas, y sus usos. 1.- Un (cis)-dibenzo[b,f]pirido[1,2-d]oxazepina-2-amina o un (cis)-dibenzo[b,f]pirido[1,2-d]tiazepina-2-amina de acuerdo con la Fórmula Ien donde R1 se selecciona del grupo (1-5C)acilo, (1-5C)tioacilo, (1-4C)alquilsulfonilo, y (1-4C)alcoxicarbonilo, cada uno se sustituye opcionalmente con uno a más átomos de halógeno; y R2 y R3 se seleccionan cada una independientemente del grupo H, halógeno, ciano, nitro, o tiocarbamilo; y R4 y R5 se seleccionan cada uno independientemente del grupo H, (1-4C)alquilo, y (1-4C)alcoxi; y X se selecciona del grupo -O-, -S-, -SO-, y -SO2-; dado que, cuando R2 es CI, R5 no es H o un racemato del mismo. 2.- Un compuesto de acuerdo con la reivindicación 1 caracterizado porque R1 es COCH3. 3.- Un compuesto de acuerdo con la reivindicación 1 caracterizado porque R1 es COCF3.4.- Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-3 caracterizado porque R2 es H. 5.- Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-3 caracterizado porque R2 es CI.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07107639 | 2007-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260140A2 true CO6260140A2 (es) | 2011-03-22 |
Family
ID=38535595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09122568A CO6260140A2 (es) | 2007-05-07 | 2009-10-29 | Nuevos moduladores del receptor de progesterona |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2155757B1 (es) |
| JP (1) | JP2010526113A (es) |
| KR (1) | KR20100021438A (es) |
| CN (1) | CN101679455A (es) |
| AR (1) | AR066467A1 (es) |
| AU (1) | AU2008248873B8 (es) |
| BR (1) | BRPI0813158A2 (es) |
| CA (1) | CA2684088A1 (es) |
| CL (1) | CL2008001333A1 (es) |
| CO (1) | CO6260140A2 (es) |
| EC (1) | ECSP099753A (es) |
| IL (1) | IL201484A0 (es) |
| MX (1) | MX2009012063A (es) |
| PE (1) | PE20090275A1 (es) |
| RU (1) | RU2009149856A (es) |
| TW (1) | TW200914029A (es) |
| WO (1) | WO2008135291A1 (es) |
| ZA (1) | ZA200907546B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019012300A2 (pt) * | 2016-12-15 | 2019-11-12 | Glaxosmithkline Ip Dev Ltd | ativadores nrf2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297685B (en) * | 2002-04-04 | 2008-06-11 | Organon Nv | Non-steroidal progesterone receptor modulators |
| TWI370129B (en) * | 2005-02-14 | 2012-08-11 | Msd Oss Bv | Non steroidal glucocorticoid receptor modulators |
-
2008
- 2008-05-02 TW TW097116259A patent/TW200914029A/zh unknown
- 2008-05-06 KR KR1020097025562A patent/KR20100021438A/ko not_active Application Discontinuation
- 2008-05-06 WO PCT/EP2008/003714 patent/WO2008135291A1/en active Application Filing
- 2008-05-06 AU AU2008248873A patent/AU2008248873B8/en not_active Ceased
- 2008-05-06 RU RU2009149856/04A patent/RU2009149856A/ru not_active Application Discontinuation
- 2008-05-06 CN CN200880015186A patent/CN101679455A/zh active Pending
- 2008-05-06 CA CA002684088A patent/CA2684088A1/en not_active Abandoned
- 2008-05-06 JP JP2010506854A patent/JP2010526113A/ja active Pending
- 2008-05-06 BR BRPI0813158-9A2A patent/BRPI0813158A2/pt not_active IP Right Cessation
- 2008-05-06 EP EP08735404A patent/EP2155757B1/en active Active
- 2008-05-06 MX MX2009012063A patent/MX2009012063A/es unknown
- 2008-05-07 AR ARP080101925A patent/AR066467A1/es not_active Application Discontinuation
- 2008-05-07 CL CL200801333A patent/CL2008001333A1/es unknown
- 2008-05-07 PE PE2008000799A patent/PE20090275A1/es not_active Application Discontinuation
-
2009
- 2009-10-13 IL IL201484A patent/IL201484A0/en unknown
- 2009-10-27 ZA ZA200907546A patent/ZA200907546B/xx unknown
- 2009-10-29 CO CO09122568A patent/CO6260140A2/es not_active Application Discontinuation
- 2009-11-20 EC EC2009009753A patent/ECSP099753A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20090275A1 (es) | 2009-03-21 |
| IL201484A0 (en) | 2010-05-31 |
| JP2010526113A (ja) | 2010-07-29 |
| AU2008248873B2 (en) | 2013-01-10 |
| ECSP099753A (es) | 2009-12-28 |
| TW200914029A (en) | 2009-04-01 |
| EP2155757A1 (en) | 2010-02-24 |
| MX2009012063A (es) | 2009-11-19 |
| AU2008248873A8 (en) | 2013-05-09 |
| CN101679455A (zh) | 2010-03-24 |
| RU2009149856A (ru) | 2011-06-20 |
| KR20100021438A (ko) | 2010-02-24 |
| EP2155757B1 (en) | 2012-10-31 |
| CL2008001333A1 (es) | 2008-10-03 |
| AR066467A1 (es) | 2009-08-19 |
| BRPI0813158A2 (pt) | 2014-12-23 |
| ZA200907546B (en) | 2010-07-28 |
| CA2684088A1 (en) | 2008-11-13 |
| AU2008248873B8 (en) | 2013-05-09 |
| AU2008248873A1 (en) | 2008-11-13 |
| WO2008135291A1 (en) | 2008-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060590A1 (es) | Compuestos imidazo | |
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR060591A1 (es) | Compuestos imidazo | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| GT200500183A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| DOP2011000217A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| CR10346A (es) | Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 | |
| UY28936A1 (es) | Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq) | |
| CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
| AR036075A1 (es) | Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden | |
| CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| TW200806328A (en) | One-part hair dye composition | |
| HN2008000179A (es) | Compuestos triciclicos,composiciones y procedimientos | |
| ECSP099394A (es) | Derivados de quinuclidinol como antogonistas de receptores muscarínicos | |
| RS53341B (en) | CIS-TETRAHYDRO-SPIRO DERIVATIVES (CYCLOHEXAN-1,1`-PYRIDO [3,4-B] INDOL) -4-AMINE | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| UY32331A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| AR067648A1 (es) | Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen | |
| CR10780A (es) | Inhibidores de cinasa | |
| CO6331307A2 (es) | Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| UY28911A1 (es) | Profármacos de esteroides con acción androgénica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |